Search results
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 4 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 4 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Lung cancer treatment produces progression-free survival results in Phase III trial
Medical Xpress· 2 days agoOsimertinib, produced by AstraZeneca under the brand name Tagrisso, significantly extends the time patients live without their cancer worsening, offering the first effective ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoTruqap™ (capivasertib) plus fulvestrant now available in Canada Canada NewsWire MISSISSAUGA, ON, May 31, 2024 MISSISSAUGA, ON, May 31, 2024 /CNW/ - AstraZeneca is pleased ...
Cramer's Lighting Round: ‘You've got a winner' with Astra Zeneca
NBC Los Angeles· 6 days ago“Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to...
Astra’s Enhertu delays breast cancer in patients with low HER2 levels
WHTC 1450 Holland· 5 days agoBy Deena Beasley (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to...
Germany’s ITM raises $205M as radiopharma field booms
BioPharma Dive via Yahoo Finance· 20 hours agoBristol Myers spent $4.1 billion to buy RayzeBio; AstraZeneca paid $2 billion for Fusion...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
The Motley Fool via AOL· 4 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth outside of obesity, so a future win in that segment would just be the icing on the cake. 2. < ...
'Outstanding' Results for Osimertinib: Stage III EGFR+ NSCLC
Medscape· 3 days agoResults from the LAURA trial will change practice once its label gets expanded, experts said at the...
Move over 'Magnificent 7,' the 'Fantastic 5' may offer higher earnings and return potential
CNBC· 17 hours agoLooking for a less risky way to find growth stocks amid all the artificial intelligence hype?...